Trial Profile
A Study Evaluating the Antitumor Effects and Biomarkers of Nivolumab in Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Mutations
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2017
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Nov 2017 New trial record
- 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer.